The single requirement that decides entry in 6 large markets

China, Japan, Brazil, Indonesia, Turkey and Argentina. Each is decided by one specific, checkable requirement, and in most cases it is not the one companies screen for.

Rankings tell you where to go. They rarely tell you what to check. This piece does the second thing: six large markets screened for a Class II medical device, and the one requirement that decides each of them.

Almost nobody publishes this half of the work, which is a pity, because the checks transfer. They apply to products and classes this assessment does not cover, and they hold up long after any ranking has gone stale.

Every market below is large, growing, or both. None of them is here for being small. Each turns on one specific, checkable requirement, named and cited. Several have reformed recently, and one has reformed its way off the list entirely.

China: no reliance route, and testing is to a Chinese standard

China turns on regulatory reliance, the criterion that separates fast markets from slow ones. There is no abridged, recognition or reliance route for a CE marked or 510(k) cleared Class II device.

Under the governing State Council decree, Class I is a filing and Classes II and III are full registrations.¹ An overseas applicant submits through a designated Chinese legal person, together with proof that the home country regulator permits marketing.² Read that carefully: the foreign approval is an eligibility document. It proves you are allowed to sell at home. It does not substitute for any part of the Chinese review.

One correction to a widely repeated claim, because it cuts the other way. Testing at an NMPA-recognised centre has not been strictly mandatory since October 2021. A self-test report is permitted.³ The binding constraint is not the laboratory, it is the standard: testing must demonstrate conformity to the Chinese product technical requirements, which reference national and industry standards.³ A foreign IEC or EN test report is not automatically sufficient.

Clinical evidence is more accommodating than its reputation. Clinical evaluation may be satisfied by trial or by analysis of literature and data on same-variety devices, and there is a published exemption catalogue, most recently reissued in May 2025.^{4 5}

Statutory technical review for Class II is 60 working days, with a further 60 after supplementary materials, and 20 days for the decision after the review opinion.⁶ Those clocks exclude applicant response time, which is where real elapsed time accumulates.

Watch this. A State Council procurement policy in force from 1 January 2026 gives domestic products a 20 percent price deduction at evaluation, with foreign-invested enterprises manufacturing in China treated as domestic.⁷ Whether medical devices and public hospital purchasing fall within its scope is not yet settled in the published instruments, and we are not going to assert it either way until the product catalogue is written.

Japan: the approval is held locally

Japan is well regulated, transparent, and publishes its review clocks. What keeps it off this list is a structural requirement rather than a slow one.

The regulator states it plainly: foreign manufacturers may submit directly to PMDA or to a registered certification body, "but in any case they should designate Marketing Authorization Holder located in Japan."⁸ Every class. No exceptions in the published guidance. The Japanese entity holds the approval and carries the efficacy, safety and quality obligations.

The route depends on class. Class I is a notification. Classes II and III can go through certification by a registered certification body, or approval. Class IV is approval by the ministry.⁹ Most Class II devices take the certification route, which involves both a product review against certification criteria and a quality system inspection against ISO 13485.¹⁰ As of March 2021 there were 12 active certification bodies and 2,565 certifications issued.¹⁰

The variable sits inside that route. Certification is available only where a certification standard exists for the device's nomenclature code. Where none exists, the device falls back to full approval, and the published review targets tell you what that costs: 4 months for a generic device, 6 to 10 months for an improved device depending on whether clinical data is required, and 14 months at the 80th percentile for a genuinely new device.¹¹

So the question that determines whether your Japanese timeline is four months or fourteen is whether a Japanese standard already covers your product code. That is checkable before you commit, and it is the check most entrants skip.

Brazil: the certificate is issued locally

Brazil is the market most often diagnosed at the wrong step.

The regulator is not the binding step. Under the current rules, Classes I and II are subject to notificação, not registro, which is a comparatively light step.¹² Most commentary has this backwards.

The binding step is conformity certification. For electromedical equipment, compulsory certification "deve ser realizada por Organismo de Certificação de Produto, OCP, estabelecido no Brasil e acreditado pelo Inmetro."¹³ A foreign CE certificate or IEC 60601 report cannot be used in place of it. The instruments are a 2021 health agency resolution mandating the certification and a 2020 metrology ordinance setting the requirements.¹³

Brazil does operate genuine reliance, but on the other axis: it is a founding member of the Medical Device Single Audit Program and recognises MDSAP audit reports for good manufacturing practice certification, with a 2024 resolution extending the validity of certificates granted that way to four years.¹⁴ That helps manufacturers of Class III and IV devices. It does not touch the electromedical certification requirement.

A Brazilian legal entity must hold the notification, supported by a declaration from the legal manufacturer authorising it to represent and commercialise the product in Brazil.¹⁵ The foreign manufacturer cannot hold it directly.

One open question we could not close, and it changes the size of the task: whether the underlying laboratory testing must physically occur in Brazil, or whether an accredited Brazilian certification body may accept a foreign test report. The metrology agency's published guidance does not address it. If foreign test reports are acceptable, Brazil is an administrative cost. If they are not, it is a re-test.

Indonesia: registration is not the deciding step

Indonesia is the clearest example of a market decided on a dimension most readiness assessments do not measure at all.

Getting a device registered is straightforward. Getting it bought is the question. Indonesian public buyers are under a statutory obligation, not a preference. The presidential regulation states that ministries, agencies and regional bodies "wajib menggunakan produk dalam negeri", are obliged to use domestic products, where the domestic content score plus the company benefit weighting reaches at least 40 percent.¹⁶

An imported device cannot generate a domestic content score. So the obligation does not merely disadvantage it. It structurally excludes it from the segment that dominates Indonesian health spending.

This has been reinforced twice since. A 2022 presidential instruction directed the health minister specifically to accelerate catalogue listings for domestic pharmaceutical and device products and to update policies favouring domestic procurement.¹⁷ A 2025 presidential regulation amended the procurement framework again with the express purpose of increasing domestic product use.¹⁸ The health ministry's own policy page records 24,361 domestic-content-certified products receiving priority "karpet merah" listing in the government e-catalogue, and publishes the content scores domestic producers achieve: 80 to 93 percent for medical apparel, 17 to 96 percent for orthopaedic implants.¹⁹

A correction worth carrying, because most published guidance on Indonesia is wrong about it: the 2017 ministerial regulation on marketing authorisation that is still cited everywhere as current is recorded by the health ministry itself as no longer in force, superseded within the risk-based business licensing framework.²⁰ If your Indonesian regulatory plan cites it, the plan is out of date.

Turkey: the currency conversion decides the price

Turkey turns on price, and the mechanism is unusually explicit and transparent.

The pricing decision in force since 13 March 2026 sets the lira value of one euro for health product pricing as the previous calendar year's average central bank euro selling rate, multiplied by an adaptation coefficient fixed at 65 percent.²¹ The mechanism is doubly suppressive: a lagged annual average, and then a statutory haircut on top of it.

The applied rate from 1 April 2026 is 29.1164 lira. The European Central Bank reference rate on 11 August 2026 was 55.0766.²² The administrative pricing euro is therefore roughly 53 percent of the market euro, an effective statutory discount of about 47 percent on the currency in which a foreign manufacturer's costs are denominated.

The reference basket is a minimum of five and a maximum of ten EU member states designated by the health ministry, with at least two months' notice of changes, and a reference product's source price is capped at 60 percent of the actual source price once equivalents enter the market.²¹

The scope caveat, stated plainly. That decision governs human medicinal products. We could not verify that the same fixed euro applies to medical devices, which are reimbursed through separate lira-denominated ceiling lists most recently reissued in January 2026.²³ Treat the fixed euro as the systemic signal about how Turkey prices health products, not as the device pricing rule, until the device schedule is separately confirmed. We are flagging this rather than smoothing over it, because the difference matters to anyone acting on it.

Argentina: the constraint was removed

Argentina is here to correct the record rather than to be excluded.

Almost every published market entry assessment still treats Argentina as a market where import payments are blocked and dividends are trapped. That was true. It has not been true since April 2025.

The central bank communication effective 14 April 2025 reduced the standard access deadline for payment of imported goods to zero days from registration of customs entry, permitted capital goods to be prepaid at sight, and opened foreign exchange market access for non-resident dividends from profits in audited annual accounts for fiscal years beginning on or after 1 January 2025.²⁴

The residual constraint is narrower and worth stating precisely, because it is still real: retained earnings from fiscal years that began before 1 January 2025 fall outside that access, and related-party service payments face a 90-day wait. A company with an Argentine subsidiary holding pre-2025 profits still cannot repatriate them under this rule.

So Argentina moves from "cannot be paid" to "can be paid, with a historical overhang." That is a different market, and anyone still screening it out on the old basis is screening out a market that no longer exists.

The pattern worth noticing

Four of these six markets turn on something other than regulatory speed.

Japan and Brazil turn on who is allowed to hold or issue a document. Indonesia turns on procurement, long after registration is complete. Turkey turns on a currency conversion coefficient. Only China turns on the thing most entry assessments actually measure, which is whether the regulatory pathway recognises work done elsewhere.

That is the argument for assessing six dimensions rather than one. A market can be straightforward to register in and very hard to sell in, and a screening process that stops at the regulator will not see that coming.

The second pattern is that two of the six entries above are corrections. Indonesia's most-cited regulation is no longer in force. Argentina's most-cited constraint was removed sixteen months ago. In a field where most published guidance is recycled, the check that pays is not "what is the rule" but "is this still the rule."

Methodology

Markets are assessed against a published six dimension framework: regulatory pathway, timeline to commercial launch, procurement structure, pricing environment, local partner requirements, and tax and customs exposure. A market does not enter the ranking when any single dimension presents a gating requirement for a foreign entrant, regardless of how it scores on the others. This is an assessment of fit for one product class at one point in time, not a judgement about a country. The framework is set out in A Structured Framework for Systematic Life Sciences Market Entry Assessment, SSRN, posted 15 June 2026, validated across 90 markets including all 50 US states. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=6913939

Every claim is sourced to a national regulator, a government legislative register, or an official gazette. Where a figure is not published, none is given. Three points we could not verify from a primary source are flagged in the text rather than estimated: the scope of China's 2026 procurement policy for medical devices, whether Brazilian conformity testing must physically occur in Brazil, and whether Turkey's fixed pricing euro applies to devices as well as medicines.

Three further markets were screened and are not included because we could not source them to the standard above: Egypt, Nigeria and Vietnam. They are held back rather than published on partial evidence.

Assessment as at 12 August 2026. Regulatory and pricing positions change; verify before acting.